Immunocore FY2026 Earnings Forecast Cut by HC Wainwright

Key Points

• HC Wainwright cut its FY2026 EPS forecast for Immunocore to a loss of $0.26 per share from a projected profit of $0.11, while maintaining a Buy rating and an $80 price target.
• Immunocore’s latest quarter came in below expectations: it reported a $0.28-per-share loss versus the $0.17 consensus and revenue of $102.22 million versus forecasts of $152.09 million.
• Analyst sentiment overall remains a Moderate Buy, with an average price target of $53; ratings are mixed, including five Buys, two Holds, and two Sells.

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) - Equities research analysts at HC Wainwright reduced their FY2026 earnings per share estimates for shares of Immunocore in a report issued on Tuesday, November 10th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.26) per share for the year, down from their previous estimate of $0.11. HC Wainwright currently has a "Buy" rating and a $80.00 target price on the stock. The consensus estimate for Immunocore's current full-year earnings is ($0.09) per share. HC Wainwright also issued estimates for Immunocore's Q4 2026 earnings at ($0.22) EPS, FY2028 earnings at $1.81 EPS, FY2029 earnings at $4.15 EPS and FY2030 earnings at $6.98 EPS.

Several other analysts have also issued reports on IMCR. Morgan Stanley set a $43.00 price target on shares of Immunocore in a research report on Friday, August 7th. JPMorgan Chase & Co. assumed coverage on shares of Immunocore in a report on Friday, August 21st. They issued an "overweight" rating and a $50.00 price objective for the company. Wall Street Zen lowered shares of Immunocore from a "buy" rating to a "hold" rating in a research note on Tuesday, July 28th. TD Cowen upgraded shares of Immunocore to a "strong-buy" rating in a research note on Monday, August 24th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Immunocore in a report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $53.00.

Immunocore Price Performance

Shares of NASDAQ:IMCR opened at $31.65 on Thursday. The company has a quick ratio of 4.44, a current ratio of 4.62 and a debt-to-equity ratio of 0.94. The firm has a market capitalization of $1.63 billion, a PE ratio of -48.69 and a beta of 0.82. Immunocore has a twelve month low of $27.50 and a twelve month high of $40.71. The company has a 50-day moving average price of $31.36 and a two-hundred day moving average price of $31.68.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its quarterly earnings data on Friday, November 6th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.11). The firm had revenue of $102.22 million during the quarter, compared to analysts' expectations of $152.09 million. Immunocore had a negative return on equity of 7.96% and a negative net margin of 7.48%.

Institutional Investors Weigh In On Immunocore

Hedge funds have recently added to or reduced their stakes in the company. Alps Advisors Inc. increased its position in shares of Immunocore by 32.7% during the 3rd quarter. Alps Advisors Inc. now owns 68,246 shares of the company's stock valued at $2,067,000 after purchasing an additional 16,826 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Immunocore in the 3rd quarter worth approximately $72,000. China Universal Asset Management Co. Ltd. lifted its position in Immunocore by 27.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,252 shares of the company's stock worth $285,000 after buying an additional 1,975 shares during the last quarter. Crossmark Global Holdings Inc. boosted its stake in Immunocore by 13.7% in the third quarter. Crossmark Global Holdings Inc. now owns 41,387 shares of the company's stock worth $1,254,000 after buying an additional 4,971 shares in the last quarter. Finally, Juncture Wealth Strategies LLC purchased a new stake in Immunocore in the third quarter worth approximately $207,000. Institutional investors own 84.50% of the company's stock.

Key Headlines Impacting Immunocore

Here are a few of the latest headlines about IMCR:

• Neutral Sentiment: Shares crossed above their 200-day moving average, a potentially supportive technical signal, despite the company’s recent quarterly earnings and revenue falling short of analyst expectations. Shares cross above 200-day moving average
• Neutral Sentiment: Immunocore presented at the Society for Immunotherapy of Cancer’s 2026 annual meeting; the provided report does not specify new findings likely to affect the stock. SITC 2026 presentation
• Negative Sentiment: HC Wainwright cut its price target to $80 from $100 and lowered several 2027 EPS estimates: Q1 to $0.17 from $0.18, Q2 to $0.26 from $0.29, and full-year estimates to $1.34 from $1.36. The retained Buy rating and higher Q4 forecast partly temper the reductions. HC Wainwright lowers expectations

About Immunocore

Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body's T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company's marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.